Stressor-responsive central nesfatin-1 activates corticotropin-releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamic-pituitary-adrenal axis

Natsu Yoshida1*, Yuko Maejima1*, Udval Sedbazar1, Akihiko Ando1, Hideharu Kurita1, Boldbaatar Damdindorj1, Eisuke Takano1, Darambazar Gantulga1, Yusaku Iwasaki1, Tomoyuki Kurashina1, Tatsushi Onaka2, Katsuya Dezaki1, Masanori Nakata1, Masatomo Mori3, and Toshihiko Yada1

1 Division of Integrative Physiology, Department of Physiology, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329-0498, Japan
2 Division of Brain and Neurophysiology, Department of Physiology, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329-0498, Japan
3 Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
*These authors contributed equally

Key words: Nesfatin-1, Stress, c-Fos, Calcium, Paraventricular nucleus, CRH, HPA axis
Received: 09/21/10; accepted: 10/10/10; published on line: 10/12/10
Corresponding author: Toshihiko Yada, PhD; E-mail: tyada@jichi.ac.jp
Copyright: © Yoshida et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract: A recently discovered satiety molecule, nesfatin-1, is localized in neurons of the hypothalamus and brain stem and colocalized with stress-related substances, corticotropin-releasing hormone (CRH), oxytocin, proopiomelanocortin, noradrenaline (NA) and 5-hydroxytryptamine (5-HT). Intracerebroventricular (icv) administration of nesfatin-1 produces fear-related behaviors and potentiates stressor-induced increases in plasma adrenocorticotropic hormone (ACTH) and corticosterone levels in rats. These findings suggest a link between nesfatin-1 and stress. In the present study, we aimed to further clarify the neuronal network by which nesfatin-1 could induce stress responses in rats. Restraint stress induced c-Fos expressions in nesfatin-1-immunoreactive neurons in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus, and in the nucleus of solitary tract (NTS), locus coeruleus (LC) and dorsal raphe nucleus (DR) in the brain stem, without altering plasma nesfatin-1 levels. Icv nesfatin-1 induced c-Fos expressions in the PVN, SON, NTS, LC, DR and median raphe nucleus, including PVN-CRH, NTS-NA, LC-NA and DR-5-HT neurons. Nesfatin-1 increased cytosolic Ca2+ concentration in the CRH-immunoreactive neurons isolated from PVN. Icv nesfatin-1 increased plasma ACTH and corticosterone levels. These results indicate that the central nesfatin-1 system is stimulated by stress and activates CRH, NA and 5-HT neurons and hypothalamic-pituitary-adrenal axis, evoking both central and peripheral stress responses.

INTRODUCTION

Nesfatin-1 is processed by cleavage of a precursor, NEFA/nucleobindin2 (NUCB2), and is distributed in the central nervous system (CNS) implicated in the regulation of feeding, including the hypothalamic paraventricular nucleus (PVN), arcuate nucleus (ARC), lateral hypothalamic area and supraoptic nucleus (SON) [1]. Double-labeling immunohistochemistry in these areas has revealed that nesfatin-1 is colocalized with feeding-related factors such as corticotropin-releasing hormone (CRH), oxytocin, proopiomelanocortin...
(POMC) and cocaine-amphetamine-regulated transcript (CART) [2-4]. Central administration of α-MSH increases NUCB2 mRNA in the hypothalamus. Anorectic effect of icv nesfatin-1 is mediated by the PVN oxytocin [5] to NTS POMC circuit [6]. Nesfatin-1 and oxytocin both suppresses food intake in Zucker-fatty rats with mutated leptin receptor, and leptin-induced satiety is unaltered by immunoneutralizing nesfatin-1 IgG [1,6]. These results suggest that nesfatin-1 induces anorexia in a leptin-independent and melanocortin-dependent manner [1,6]. It has also been reported that the anorectic action of nesfatin-1 involves the CRH pathway [7]. The CRH and melanocortin [10] pathways are implicated in stress.

Several studies have suggested a possible link of nesfatin-1 to stress responses. Nesfatin-1 is distributed in the stress-related areas, including the nucleus of solitary tract (NTS), locus coeruleus (LC) and raphe pallidus nucleus (RPa) [3] as well as PVN. Furthermore, nesfatin-1 is colocalized with CRH in the PVN and with noradrenaline (NA) and 5-hydroxytryptamine (5-HT) in the brain stem [3]. CRH in the PVN drives release of ACTH and corticosterone, evoking the hypothalamic-pituitary-adrenal (HPA) axis characteristically implicated in the stress responses, and NA and 5-HT modulate the HPA axis. Peripheral injection of 5-HT2C agonist increases NUCB2 mRNA in the hypothalamus [8]. Central administration of nesfatin-1 produces anorexigenic and fear-related behaviors in several animal models [9]. Nesfatin-1 activates melanocortin pathway [1,6] implicated in stress responses [10]. Based on these observations, we hypothesized that nesfatin-1 could serve as a stress mediator. Nesfatin-1 is also localized in the peripheral tissues including stomach [11,12], pancreas [13,14] and adipose tissue [15], though its function remains largely unknown.

This study aimed to clarify whether the central nesfatin-1 system and/or the plasma nesfatin-1 level is activated by restraint stress, to specify the central areas and neuron species targeted by stress and icv nesfatin-1, and to examine whether icv nesfatin-1 stimulates HPA axis in rats. c-Fos protein expression was examined to detect neuronal activation. Direct effects of nesfatin-1 on specified neurons were determined by measurement of cytosolic Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_i\)) in isolated neurons combined with immuno-cytochemistry. We here show that the central nesfatin-1 is stimulated by stressor and that icv nesfatin-1 activates CRH, NA and 5-HT neurons and HPA axis.

**RESULTS**

Nesfatin-1 was colocalized with TH in the NTS and LC

Double fluorescence immunohistochemistry in the LC showed that immunoreactivity for TH (Figure 1A) and that for nesfatin-1 (Figure 1B) overlapped extensively in neurons in the LC (Figure 1C), demonstrating colocalization of two molecules in the LC neurons. Similarly, immunoreactivities for TH (Figure 1D) and nesfatin-1 (Figure 1E) overlapped in neurons in the NTS (Figure 1F), confirming previous reports [3, 17].

**Figure 1. Dual immunofluorescence histochemistry for nesfatin-1 and tyrosine hydroxylase (TH).**

(A-C) Neurons immunoreactive (IR) to nesfatin-1 (green) (A) and TH (red) (B), and their merged image (C) in the LC. (D-F) Neurons IR to nesfatin-1 (green) (D) and TH (red) (E), and their merged image (F) in the NTS. Colocalization of nesfatin-1 with TH is seen by yellow color in (C) and (F). Scale bar, 100 μm. 4V, forth ventricle.
Restraint stress induced c-Fos expressions in nesfatin-1 neurons in the hypothalamus and brain stem but failed to alter plasma nesfatin-1 concentrations

Exposure of rats to restraint stress for 60 min, as compared to control groups without stress, induced c-Fos expression in the areas of the hypothalamus and brain stem where nesfatin-1 is localized. In the PVN, the number of c-Fos immunoreactive (IR) neurons in stress groups (180.3 ± 13.5 neurons/section, n = 12 slices) were significantly (P < 0.01) greater than those in control groups (5.8 ± 1.0 neurons/section, n = 13) (Figures 2A and G). In these c-Fos-expressing neurons, 47.1 ± 3.2% was IR to nesfatin-1. Conversely, 32.0 ± 2.0% of nesfatin-1-IR neurons expressed c-Fos in stress groups, while only 1.5 ± 0.4% in control groups (Figures 2A and F). Stress also induced significant c-Fos expression in nesfatin-1 neurons in the SON, ARC, NTS and LC (Figures 2B-E and F). c-Fos expression was significantly increased (9.3 ± 2.0, n = 17, in stress group vs. 0.2 ± 0.1, n = 22, in control group, P < 0.01) in the DR. The nesfatin-1 level in the blood from jugular vein in rats after exposure to restraint stress for 15 min (2.5 ± 0.4 ng/ml, n = 3) was not different from that in control rats (2.5 ± 0.2 ng/ml, n = 3), and the nesfatin-1 level in the blood from portal vein was not different between stress (3.1 ± 0.5 ng/ml, n = 3) and control groups (3.0 ± 0.2 ng/ml, n = 3) (Figure 2G).

Figure 2. c-Fos expressions on nesfatin-1 neurons in several brain areas and plasma nesfatin-1 levels after restraint stress. (A-E) Double-immunohistochemical staining of c-Fos (black) and nesfatin-1 (brown) in the PVN (A), SON (B), ARC (C), NTS (D) and LC (E) in control conditions (left panels) and after restraint stress (right panels). White arrows indicate nefatin-1-IR neurons, black arrows c-Fos-IR neurons, and blue arrows both-IR neurons. (F) Incidence of c-Fos-IR neurons in nesfatin-1-IR neurons, as expressed by percentage. Number of c-Fos was significantly greater in stress than control conditions in the PVN and ARC, and found only in stress conditions in SON, NTS and LC. **p < 0.01 vs. control. (G) Nesfatin-1 concentrations in the plasma of jugular vein and portal vein were not different between control and stress conditions.
We next examined which of the brain areas could be activated by icv nesfatin-1. Injection of nesfatin-1 into 3v (0.5 nmol/5 μl) significantly increased the number of neurons that expressed c-Fos in the PVN (nesf-1; 62.3 ± 4.2, n = 22 slices, vs. saline; 27.2 ± 3.8, n = 20 slices; Figure 3-A,H), SON (B,H), NTS (D,H), LC (E,H), DR (F,H) and MR (G,H), while no difference was observed between two groups in the ARC (C,H). *p < 0.05, **p < 0.01 vs. control.

**Figure 3. c-Fos expressions in several brain areas after icv administration of nesfatin-1.** The number of c-Fos was significantly greater in the group treated with icv nesfatin-1 (0.5 nmol / 5 μl) than in control saline-treated group in the PVN (A,H), SON (B,H), NTS (D,H), LC (E,H), DR (F,H) and MR (G,H), while no difference was observed between two groups in the ARC (C,H). *p < 0.05, **p < 0.01 vs. control.

**Icv administration of nesfatin-1 induced c-Fos expression in stress-related nuclei**

We next examined which of the brain areas could be activated by icv nesfatin-1. Injection of nesfatin-1 into 3v (0.5 nmol/5 μl) significantly increased the number of neurons that expressed c-Fos in the PVN (nesf-1; 62.3 ± 4.2, n = 22 slices, vs. saline; 27.2 ± 3.8, n = 20 slices; Figure 3-A,H), SON (nesf-1; 10.7 ± 3.0, n = 31, vs. saline; 3.2 ± 1.0, n = 27; Figure 3-B,H), NTS (nesf-1; 22.1 ± 3.5, n = 23, vs. saline; 12.2 ± 1.7, n = 20; Figure 3-D,H), LC (nesf-1; 38.0 ± 7.5, n = 32, vs. saline; 7.1 ± 1.6, n = 15; Figure 3-E,H), dorsal raphe nucleus (DR) (nesf-1; 152.2 ± 25.2, n = 29, vs. saline; 23.0 ± 3.7, n = 25; Figure 3-F,H) and median raphe nucleus (MR) (nesf-1; 12.5 ± 4.9, n = 18, vs. saline; 0.1 ± 0.1, n = 14; Figure 3-G,H). Nesfatin-1 failed to induce c-Fos in the ARC (Figure 3-C,H).

**Icv nesfatin-1 induced c-Fos expression in neurons containing stress-related neurohormones**

We intended to identify the target neurons for central nesfatin-1 by double immunohistochemistry. Icv
administration of nesfatin-1 induced c-Fos expression in CRH neurons in the PVN (Figure 4A): the incidence of c-Fos expression in CRH neurons was significantly (P < 0.05) higher after nesfatin-1 treatment (28.3 ± 7.7%, n = 12 slices) compared to saline treatment (3.9 ± 1.0%, n = 9) (Figure 4E). Vice versa, a large fraction of the c-Fos-expressing neurons after icv nesfatin-1 (44.2 ± 6.7%, n = 12) contained CRH. These data indicated that CRH neuron was a major target of icv nesfatin-1 in the PVN. In the DR, icv nesfatin-1 increased the incidence of c-Fos expression in tryptophan hydroxylase (TPH)-IR neurons (nesf-1; 15.1 ± 3.3%, n = 29 vs. saline; 5.8 ± 2.2%, n = 27, P < 0.05) (Figures 4B and E). Vice versa, 15.3 ± 2.3% of the neurons that expressed c-Fos after icv nesfatin-1 contained TPH. These data indicated that 5-HT neuron was a target of icv nesfatin-1 in the DR. In the NTS, icv nesfatin-1 increased the incidence of c-Fos expression in TH-IR neurons (nesf-1; 15.4 ± 4.9%, n = 24, vs. saline; 1.6 ± 0.5%, n = 21, P < 0.05) (Figures 4D and E). Vice versa, 23.9 ± 4.2% (n = 22) of the neurons that expressed c-Fos after icv nesfatin-1 contained TH. These data indicated that noradrenaline neuron was a substantial target of icv nesfatin-1 in the NTS. In the LC, nesfatin-1 induced a marked c-Fos expression in TH-IR neurons (Figure 4E). However, it was difficult to count c-Fos-expressing TH-IR neurons since neurons extensively overlapped to each other. In addition, icv nesfatin-1 also increased the incidence of c-Fos expression in oxytocin neurons in the PVN (data not shown), confirming our previous report [6].

Figure 4. c-Fos expressions in stress-related neurons after icv administration of nesfatin-1. (A-D) Double-immunohistochemical staining of c-Fos (black) together with CRH (brown) in PVN (A), with tryptophan hydroxylase (TPH) in DR (B), with TH in NTS (C) and LC (D) after icv saline (left panels) and nesfatin-1 (right panels). (E) Incidence of c-Fos-IR neurons in CRH-IR, TPH-IR and TH-IR neurons in the corresponding areas, respectively. Scale bars, 100 μm. 4V, forth ventricle. White arrows indicate CRH-, TPH- or TH-IR neurons, black arrows c-Fos-IR neurons, and blue arrows both-IR neurons. *p < 0.05 vs. saline.
Nesfatin-1 increased \( [\text{Ca}^{2+}]_i \) in single CRH neurons in the PVN

The results that icv nesfatin-1 induced c-Fos in CRH neurons raised a question whether nesfatin-1 could directly interact with this neuron. Administration of \( 10^{-10} \) M nesfatin-1 increased \( [\text{Ca}^{2+}]_i \) in a single neuron isolated from the PVN (Figure 5A, left), and the neuron was subsequently shown to be immunoreactive to CRH (Figure 5A, right). Nesfatin-1 at \( 10^{-10} \) M increased \( [\text{Ca}^{2+}]_i \) in 4 out of 16 PVN CRH-IR neurons (25%). The results revealed that nesfatin-1 directly interacts with and increases \( [\text{Ca}^{2+}]_i \) in the PVN CRH neurons.

The effect of central nesfatin-1 on plasma ACTH and corticosterone levels

The result that nesfatin-1 activated CRH neurons suggested a possibility that this action is linked to the HPA axis. Icv nesfatin-1 significantly increased the plasma ACTH levels at 10 min after administration, compared to icv saline (247.1 ± 46.8 pg/ml (n = 15) with nesfatin-1 vs. 143.4 ± 14.7 pg/ml (n = 15) with saline, \( p < 0.05 \)). Icv nesfatin-1 also significantly increased the plasma corticosterone levels at 15 min after administration, compared with control (228.0 ± 54.9 ng/ml (n = 11) with nesfatin-1 vs. 100.4 ± 20.6 ng/ml (n = 11) with saline, \( p < 0.05 \)). The elevated levels of ACTH and corticosterone returned to the basal levels at 30 and 60 min after administration, respectively (data not shown). These data demonstrate that icv nesfatin-1 evokes CRH-ACTH-corticosterone pathway HPA axis.

**DISCUSSION**

The present study has demonstrated that the central nesfatin-1 system but not the plasma nesfatin-1 level is activated by restraint stress and that icv nesfatin-1 activated CRH, noradrenaline and 5-HT neurons and increases plasma ACTH and glucocorticoid levels.

In this study, restraint stress induced abundant c-Fos expressions in nesfatin-1 neurons in the stress-related brain areas, PVN, SON, NTS and LC, confirming the recent report by Goebel et al. [17]. More importantly, we have found for the first time that centrally administered nesfatin-1 induced significant c-Fos expression in PVN, SON, NTS, LC, DR and MR, including more specifically the CRH neurons of PVN, the NA neurons of NTS and LC, and the 5-HT neurons of DR. In addition, we have first demonstrated that nesfatin-1 directly interacted with and increased \( [\text{Ca}^{2+}]_i \) in the CRH neurons isolated from PVN, and that centrally administered nesfatin-1 by itself, with no added stress, increased plasma ACTH and corticosterone levels. These results collectively demonstrate that the nesfatin-1 neuronal system in the hypothalamus and brain stem respond to stressor and evokes central stress responses leading to activation of the HPA axis. This mechanism may underlie the nesfatin-1-induced stress-related behaviors [18].

In the present study, we confirmed previous report that nesfatin-1 is colocalized with NA in the NTS [3] and added that nesfatin-1 is also colocalized with NA in the LC, the area of the largest source of NA neurons. We
also confirmed the finding by Goebel et al. [17] that the nesfatin-1 neurons in the PVN, SON, LC, and NTS are activated by stress and added that those in the ARC are also activated by stress and that plasma nesfatin-1 concentrations are altered neither by restraint stress nor by a stronger stress of water immersion-restraint (data not shown). These results suggest that the central but not peripheral nesfatin-1 is involved in stress responses.

We showed that icv injection of nesfatin-1 induces c-Fos expression in CRH, NA and 5-HT neurons in the PVN, NTS and DR, respectively. In particular, a large fraction (28.3%) of CRH neurons expresses c-Fos in the PVN after icv nesfatin-1. Furthermore, nesfatin-1 directly interacts with and increases [Ca$^{2+}$], in a substantial fraction (25%) of CRH neurons isolated from the PVN, in accord with previous report that nesfatin-1 changes electrical activities of CRH neurons [19]. Thus, nesfatin-1 activates CRH neurons both in vivo and ex vivo. These results demonstrate that nesfatin-1 targets the PVN CRH neurons.

In the present study we have demonstrated that icv nesfatin-1 increases plasma ACTH and corticosterone concentrations confirming the previous report [20]. After icv administration of nesfatin-1, plasma ACTH and corticosterone levels increased at 10 and 15 min and returned toward basal levels at 30 and 60 min, respectively. This time course of plasma ACTH levels fits with the reports that plasma ACTH concentrations increase maximally at 5-15 min after administration of several stress-related neuro-peptides [21-23] and under restraint stress conditions [24].

On the other hand, our data of the time course of plasma corticosterone levels appear somewhat shorter-lasting than those previously reported in which the plasma corticosterone reaches and keeps maximum levels during 30-120 min, and then declines to the basal levels [23,25]. Our data of relatively shorter-lasting increase of plasma corticosterone by icv nesfatin-1 may suggest that the central nesfatin-1 is implicated in the initiation or the early phase of stress responses.

It has been shown that nesfatin-1 is localized not only in the central nervous system but in the peripheral tissues including stomach [11,12], pancreas [13,14], and adipose tissue [15]. The present study indicated that stress induced c-Fos in the nesfatin-1 neurons without altering plasma nesfatin-1 levels. The results suggest that stress involves the central but not circulating nesfatin-1. The precise neural mechanism by which nesfatin-1 neurons mediate stress responses remain to be elucidated. However, the nesfatin-1 neurons in the stress-activated nuclei such as NTS, LC and SON may project to the PVN CRH neurons. Alternatively, stress-activated nesfatin-1 neurons in the PVN may activate CRH neurons via a paracrine and/or ultrashort feedback regulation, which is supported by that nesfatin-1 is localized in secretory vehicles in PVN neurons [6].

We found that central nesfatin-1 also activates NA neurons in the NTS and LC and 5-HT neurons in the DR of the brain stem. It has been documented that these NA and 5-HT neurons project to PVN [26-28] including CRH neurons [29-31], being relayed to activation of HPA axis [32-35]. Our data together with these documents suggest that the nesfatin-1-activated NA and 5-HT neurons project to and stimulate PVN CRH neurons and that this pathway partly contributes to the nesfatin-1 activation of HPA axis.

We found that icv nesfatin-1 induces c-Fos expression in 5-HT neurons. Vice versa, peripheral injection of a 5-HT receptor agonist reportedly increases NUCB2 mRNA expressions in the hypothalamus [8]. These findings suggest a bidirectional interaction between 5-HT and nesfatin-1 neurons.

In summary, this study presents evidence to support that stressor-responsive nesfatin-1 neurons in the hypothalamus and brain stem activate the CRH, NA and 5-HT neurons and evoke HPA axis, thus inducing stress responses. Central nesfatin-1 system could provide a potential therapeutic target for treating stress-related disorders in humans.

**METHODS**

**Animals.** Male Sprague Dawley rats aged 7-8 weeks were housed in individual cages and maintained under a controlled environment (12h/12h dark/light cycle, lights on at 07:30) and allowed free access to conventional food (CE-2; Clea, Osaka, Japan) and water ad libitum. All procedures were performed in accordance with institutional guidelines for Animal Care at Jichi Medical University.

**Restraint stress.** Rats were wrapped in a wire mesh and kept in their cages for 15 or 60 min. Control rats were left in their cages without any treatment. At the termination of the stress period, animals were released from a wire mesh. The stress was given in day time (10:00-14:00h).

**Intracerebroventricular cannulation.** Rats were anesthetized by injection of Avertin (Trichloremethanol, 200 mg/kg, ip) and placed in a stereotaxic frame (DAVIO Kopf Instruments, Tujunga, CA), and a stainless steel guide cannula (26 gauge) was inserted into the brain with the tip in the third ventricle (3v): 2.5 mm posterior from the bregma and 8 mm below the skull). Rats were
allowed 9-11 days to recover from the surgical procedure and were handled daily to minimize non specific stress responses. Substances were administered into 3v via a stainless steel injector (30 gauge) through the guide cannula. Rats received an administration of 0.5 nmol nesfatin-1 in 5 μl of 0.9 % NaCl into 3v. Experiments were carried out during the light phase (for immunohistochemical study at 10:00-14:00h, and for blood collection at 10:00-11:00h). Hypothalamic sections were histologically examined at the end of the study, and the placement of the cannula was verified. The rats in which cannulae were outside 3v were excluded from the data analysis.

Tissue preparation for immunohistochemistry. At 2 h after 60 min restraint stress and at 2 h after icv administration of nesfatin-1, rats were deeply anesthetized with urethane (1 g/kg, ip) and perfused with saline containing heparin (20 U/ml) and then 4% paraformaldehyde in 0.1 M phosphate buffer. The brains were immediately removed, postfixed in the same fixative overnight at 4°C, and then immersed in PBS containing 30% sucrose for at least 2 days at 4°C. The brains were frozen on dry ice and kept at -80°C until sectioning. Frozen frontal sections (40 μm) were prepared with a freezing microtome and collected at 240 μm intervals. In immunohistochemical studies, each quantitative analysis was performed in 9 to 32 sections collected from 3 animals.

Double-labeling immunohistochemistry for nesfatin-1 and TH. Fixed brain sections were prepared during 10:00-14:00h as described above. Sections were rinsed in PBS, and then incubated in 0.3% TritonX containing PBS (PBST) for 30 min and then blocked for 30 min in 2% BSA-containing PBST. Finally, sections were incubated with rabbit anti-nesfatin-1 antibody (1:1000) (Oh-I et al. 2006) and mouse monoclonal anti-tryptophan hydroxylase clone TH2 antibody (Sigma Aldrich, MO ;1:4000) overnight at 4°C. Then the sections were rinsed and incubated with biotinylated goat anti-rabbit IgG (Vector Laboratories, CA; 1:500) for 30 min and then with ABC reagent (Vector Laboratories, CA; ABC KIT) for 30 min. After the rinse in PBS and 0.05 M Tris-HCl buffer (pH7.4), color was developed with a nickel-diaminobenzidine (DAB) solution (0.2 g/liter DAB and 0.015 % H2O2 in 0.05 M Tris-HCl buffer (pH7.4)) for 5 min. Slices were mounted on slides and coverslipped with Entellan new (Merck, Darmstadt, Germany).

Double-labeling immunohistochemistry for c-Fos and nesfatin-1, CRH, NA or 5-HT. Double-labeling immunohistochemistry for c-Fos together with nesfatin-1, CRH, NA or 5-HT was performed by the procedures stated above and according to Kohno et al. [2]. Rabbit anti nesfatin-1 antibody (1:5000) [1], rabbit anti CRH antibody (BACHEM, CA, 1:5000), mouse monoclonal anti-TH2 antibody (Sigma Aldrich, 1:4000) or mouse monoclonal anti-tryptophan hydroxylase (Ab-1) antibody (Calbiochem, 1:800) was used for each neuropeptide staining.

Measurement of [Ca^{2+}] in single PVN neurons. [Ca^{2+}] was measured by radiometric fura-2 microfluorometry in combination with digital imaging as previously reported [6]. Briefly, following incubation with 2 μmol/l fura2/AM (Dojin Chemical, Kumamoto, Japan) for 1 h at 18°C, the cells were mounted in a chamber and superfused with HKRB at 1 ml/min at 33°C. Fluorescence images due to excitation at 340 and 380 nm were detected every 8.0 s with an intensified charge-coupled device (ICCD) camera, and the ratio (F340/F380) image was produced due to excitation at 340 and 380 nm were detected every 8.0 s with an intensified charge-coupled device (ICCD) camera, and the ratio (F340/F380) image was produced by an Argus-50 system (Hamamatsu Photonics, Hamamats, Japan). When [Ca^{2+}] increased within 5 min after addition of nesfatin-1 with the ratio changes greater than 0.3, they were considered responses. Data were taken from the cells that were identified as neurons by the criteria reported previously [16].

Effect of stress on plasma nesfatin-1 levels. After restraint stress for 15 min given in day-time (10:00-14:00h), rats were anaesthetized by injection of urethane (1 g/kg, ip) and then blood were collected from jugular vein or portal vein. After addition of 1/10 amounts of 1 N HCl to the plasma, plasma was stored at -80°C until the measurement of nesfatin-1. The plasma nesfatin-1 concentrations were measured with a RIA kit (Phoenix Pharmaceuticals, Inc., CA).
Effect of 3v nesfatin-1 administration on plasma ACTH and corticosterone levels. At 10 min (for ACTH) or 15 min (for corticosterone) after icv administration of nesfatin-1, rats were decapitated and blood was collected into tubes containing EDTA and aprotinin. Plasma was separated from blood and stored at -80°C until the measurement of ACTH or corticosterone. The plasma ACTH concentrations were measured with a RIA kit (Mitsubishi Chemical Medience Co., Tokyo, Japan) and plasma corticosterone concentrations with an ELISA kit (Assaypro, MO). These studies were performed during day-time (10:00-11:00h).

Statistics. All data were presented as the means ± SEM (n = number of animals or slices). Statistical analysis was carried out using Student’s t test for two-group experiments. The statistical significance level was set at P < 0.05.

ACKNOWLEDGEMENTS

This work was supported by Grant-in-Aid for Scientific Research (B) (18390065, 20390061) and that for Challenging Exploratory Research (22659044) from Japan Society for the Promotion of Science (JSPS), a Support Program for Strategic Research Platform for Private University from Ministry of Education, Culture, Sports, Science and Technology Japan, a grant from the Smoking Research Foundation, an Insulin Research Award from Novo Nordisk, and a grant from Takeda Science Foundation to TY, and by Grant-in-Aid for Young Scientists (B) (20790633) from JSPS and Jichi Medical University Young Investigator Award to YM. This study was subsidized by JKA through its promotion funds from KEIRIN RACE to TY.

CONFLICT OF INTERESTS STATEMENT

The authors of this manuscript have no conflict of interests to declare.

REFERENCES

1. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443:709-712.
2. Kohno D, Nakata M, Maejima Y, Shimizu H, Sedbazar U, Yoshida N, Dezaki K, Onaka T, Mori M, and Yada T. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology. 2008; 149:1295-1301.
3. Brailoiu GC, Dun SL, Brailoiu E, Inan S, Yang J, Chang JK, and Dun NJ. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology. 2007; 148:5088-5094.
4. Foo KS, Brismar H, and Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience. 2008; 156:563-579.
5. Yosten GL, and Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol. 2010; 298:R1642–R1647.
6. Maejima Y, Sedbazar U, Suyama S, Kohno D, Onaka T, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, et al. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metabolism 2009; 10:355-365.
7. Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Mönnikes H, Lambrecht NW, and Taché Y. Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology. 2009; 150:4911-4919.
8. Nonogaki K, Ohba Y, Sumii M, and Oka Y. Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5-HT2C receptors and induce anorexia via a leptin-independent pathway in mice. Biochem Biophys Res Commun. 2008; 372:186-1890.
9. Merali Z, Cayer C, Kent P, and Anisman H. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl). 2008; 201:115-123.
10. Liu J, Garza JC, Truong HV, Henschel J, Zhang W, and Lu XY. The melanocortinergic pathway is rapidly recruited by emotional stress and contributes to stress-induced anorexia and anxiety-like behavior. Endocrinology. 2007; 148:5531-5540.
11. Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Taché Y, Sachs G, and Lambrecht NW. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology. 2009; 150:232-238.
12. Stengel A, Goebel M, Wang L, and Taché Y. Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A_like cells: role as regulators of food intake and body weight. Peptides. 2010; 31:357-369.
13. Gonzalez R, Tiwari A, and Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun. 2009; 381:643-648.
14. Foo KS, Brauner H, Ostenson CG, and Broberger C. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol. 2010; 204:255-263.
15. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, and Randeva HS. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010; 151:3169-3180.
16. Muroya S, Yada T, Shioda S, and Takigawa M. Glucose-sensitive neurons in the rat arcuate nucleus contain neuropeptide Y. Neurosci Lett. 1999; 264:113-116.
17. Goebel M, Stengel A, Wang L, and Taché Y. Restraint stress activates nesfatin-1-immunoreactive brain nuclei in rats. Brain Res. 2009; 1300:114-124.
18. Merali Z, Cayer C, Kent P, and Anisman H. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl). 2008; 201:115-123.

19. Price CJ, Hoyda TD, Samson WK, and Ferguson AV. Nesfatin-1 influences the excitability of paraventricular nucleus neurones. J Neuroendocrinol. 2008; 20:245-250.

20. Könczöl K, Bodnár I, Zelena D, Pintér O, Papp RS, Palkovits M, Nagy GM, and Tóth ZE. Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. Neurochem Int. 2010; 57:189-197.

21. Matsumoto H, Maruyama M, Noguchi J, Horikoshi Y, Fujiwara K, Kitada C, Hinuma S, Onda H, Nishimura O, Inoue K, and Fujino M. Stimulation of corticotropin-releasing hormone-mediated adrenocorticotropic hormone secretion by central administration of prolactin-releasing peptide in rats. Neurosci Lett. 2000; 285:234-238.

22. Itoi K, Helmreich DL, Lopez-Figueroa MO, and Watson SJ. Differential regulation of corticotropin-releasing hormone and vasopressin gene transcription in the hypothalamus by norepinephrine. J Neurosci. 1999; 19:5464-5472.

23. Smith KL, Patterson M, Dhillon WS, Patel SR, Semjenov NM, Gardiner JV, Ghaetei MA, and Bloom SR. Neuropeptide S stimulates the hypothalamic-pituitary-adrenal axis and inhibits food intake. Endocrinology. 2006; 147:3510-3518.

24. Noguchi T, Makiko S, Maruyama H, and Hashimoto K. Regulation of proopiomeLANOCORTIN gene transcription during single and repeated immobilization stress. Neuroendocrinology. 2006; 84:21-30.

25. Vrang N, Larden PJ, Kristensen P, and Tang-Christensen M. Central administration of cocaine-anphetamine-regulated transcript activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 2000; 141:794-801.

26. Cunningham ET Jr, and Sawchenko PE. Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J Comp Neurol. 1988; 274:60-76.

27. Sawchenko PE, Swanson LW, Steinbusch HW, and Verhofstad AA. The distribution and cells of origin of serotoninergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res. 1983; 277:355-360.

28. Dong YX, Han ZA, Xiong KH, and Rao ZR. Fos expression in serotoninergic midbrain neurons projecting to the paraventricular nucleus of hypothalamus after noxious stimulation of the stomach: a triple labeling study in the rat. Neurosci Res. 1997; 27:155-160.

29. Itoi K, Suda T, Tozawa F, Dobashi I, Ohmori N, Sakai Y, Abe K, and Demura H. Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats. Endocrinol. 1994; 135:2177-2182.

30. Liposits Z, Phelix C, and Paull WK. Synaptic interaction of serotoninergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A light and electron microscopic immunocytochemical study. Histochemistry. 1987; 86:541-549.

31. Jørgensen H, Knigge U, Kjaer A, Møller M, and Warberg J. Serotoninergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression. J Neuroendocrinol. 2002; 14:788-795.